Acceleron has positive prelim data in Phase 2 hypertension trial

 Treatment with sotatercept in the ongoing SPECTRA Phase 2 trial was associated with improvements in resting and exercise hemodynamics at week 24 –

– Sotatercept was generally well tolerated, consistent with the previously reported safety profile in PAH and in other diseases –

- Company-hosted investor and analyst conference call and webcast with guest PAH key opinion leader to be held today, Wednesday, May 19th at 10:30 a.m. EDT –

Detailed presentation is available on the "Publications" page under the "Science & Pipeline" section of Acceleron’s website, www.acceleronpharma.com.

https://finance.yahoo.com/news/acceleron-presents-preliminary-data-spectra-120000149.html